These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19395471)

  • 1. Immune-based therapy for chronic hepatitis C.
    Chang DY; Shin EC
    J Leukoc Biol; 2009 Jul; 86(1):33-9. PubMed ID: 19395471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for HCV infection: next steps.
    Lang K; Weiner DB
    Expert Rev Vaccines; 2008 Sep; 7(7):915-23. PubMed ID: 18767942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunology of hepatitis C: clinical significance of T cell response].
    Shin EC
    Korean J Hepatol; 2006 Jun; 12(2):140-53. PubMed ID: 16804339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccination against chronic hepatitis C virus infection.
    Ip PP; Nijman HW; Wilschut J; Daemen T
    Antiviral Res; 2012 Oct; 96(1):36-50. PubMed ID: 22841700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of hepatocellular carcinoma complicating chronic hepatitis C.
    Ueno Y; Sollano JD; Farrell GC
    J Gastroenterol Hepatol; 2009 Apr; 24(4):531-6. PubMed ID: 19368633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Codelivery of PEG-IFN-alpha inhibits HCV DNA vaccine-induced T cell responses but not humoral responses in African green monkeys.
    Park SH; Lee SR; Hyun BH; Kim BM; Sung YC
    Vaccine; 2008 Jul; 26(32):3978-83. PubMed ID: 18556097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.
    Lauer GM
    J Infect Dis; 2013 Mar; 207 Suppl 1():S7-S12. PubMed ID: 23390305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.
    Wedemeyer H; Schuller E; Schlaphoff V; Stauber RE; Wiegand J; Schiefke I; Firbas C; Jilma B; Thursz M; Zeuzem S; Hofmann WP; Hinrichsen H; Tauber E; Manns MP; Klade CS
    Vaccine; 2009 Aug; 27(37):5142-51. PubMed ID: 19559112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chronic HCV infections. A model disease for therapy, economics and social-medical aspects].
    Rossol S
    Gesundheitswesen; 2007 Mar; 69(3):146-50. PubMed ID: 17440844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serine protease inhibitors as anti-hepatitis C virus agents.
    Reiser M; Timm J
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):537-47. PubMed ID: 19485794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir: hope on the horizon, getting closer.
    Weisberg IS; Jacobson IM
    Clin Liver Dis; 2009 Aug; 13(3):441-52. PubMed ID: 19628160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intra portal donor specific antigen transfusion might prevent re-infection of hepatitis C virus after living related liver transplantation in hepatitis C hepatic cirrhosis.
    Sato Y; Oya H; Yamamoto S; Kobayashi T; Watanabe T; Kokai H; Yamagiwa S; Hatakeyama K
    Hepatogastroenterology; 2009; 56(89):205-7. PubMed ID: 19453058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of hepatitis C.
    Pan JJ; Firpi RJ
    Minerva Gastroenterol Dietol; 2009 Mar; 55(1):23-35. PubMed ID: 19212305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in viral kinetics between genotypes 1 and 2 of hepatitis C virus after single administration of standard interferon-alpha.
    Toyoda H; Kumada T; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Kanamori A; Atsumi H; Takagi M; Nakano S; Arakawa T; Fujimori M
    J Med Virol; 2009 Aug; 81(8):1354-62. PubMed ID: 19551828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Extrahepatic manifestations of chronic hepatitis C virus infection].
    Puchner KP; Berg T
    Z Gastroenterol; 2009 May; 47(5):446-56. PubMed ID: 19418414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects of RNAi and microRNA-based therapies for hepatitis C.
    Pan Q; Tilanus HW; Janssen HL; van der Laan LJ
    Expert Opin Biol Ther; 2009 Jun; 9(6):713-24. PubMed ID: 19456206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current clinical care compared with new Dutch guidelines for hepatitis C treatment.
    Slavenburg S; Lamers MH; Roomer R; de Knegt RJ; van Oijen MG; Drenth JP
    Neth J Med; 2009 May; 67(5):177-81. PubMed ID: 19581667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of the novel oral vaccine against hepatitis C virus utilizing bifidobacteria].
    Shirakawa T
    Nihon Rinsho; 2015 Feb; 73(2):239-42. PubMed ID: 25764677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.